Love, S., Kerr, R., Segelov, E., Johnstone, E., Falcon, B., Hewett, P., . . . Kerr, D. (2016). Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): An open-label, randomised phase 3 trial. Lancet.
芝加哥风格引文Love, S., et al. Adjuvant Capecitabine Plus Bevacizumab Versus Capecitabine Alone in Patients with Colorectal Cancer (QUASAR 2): An Open-label, Randomised Phase 3 Trial. Lancet, 2016.
MLA引文Love, S., et al. Adjuvant Capecitabine Plus Bevacizumab Versus Capecitabine Alone in Patients with Colorectal Cancer (QUASAR 2): An Open-label, Randomised Phase 3 Trial. Lancet, 2016.
警告：这些引文格式不一定是100％准确.